|
|
Post by peppy on Feb 1, 2023 12:54:17 GMT -5
Peppy. Do you make anything of the price bouncing off 5.28 3 times today? I get it now! The 4th time it goes thru it! yes, 4th time through. |
|
|
|
Post by peppy on Feb 1, 2023 12:53:42 GMT -5
Peppy. Do you make anything of the price bouncing off 5.28 3 times today? No, do you? |
|
|
|
Post by peppy on Feb 1, 2023 10:31:11 GMT -5
MNKD Volume at 1 hour of trade,
514,547 shares
Avg. Volume 4,411,175
$5.35 -0.12 (-2.13%)
As of 10:30AM EST. Market open.
|
|
|
|
Post by peppy on Jan 31, 2023 17:40:46 GMT -5
|
|
|
|
Post by peppy on Jan 31, 2023 16:19:44 GMT -5
MNKD Nasdaq real time volume, 5,149,146 shares. .............( times $5.47 = $28 million. ) MNKD Nasdaq summary volume, 5,067,226 Avg. Volume 4,389,191 $5.47. +0.32 +6.21%) daily charts MNKD, up on volume, thank you Mike. schrts.co/MEgxCSghMNKD Monthly, the month has ended. schrts.co/WsMjhIqX$COMPQ daily. Well look here on the daily $compq. See all the trend lines bundled up all about to cross each other tomorrow, pointing up. $COMPQ through it's 200 day. schrts.co/tkThwcBK$COMPQ Monthly schrts.co/qDKPUwsB |
|
|
|
Post by peppy on Jan 31, 2023 11:47:58 GMT -5
Point of break out , point of cup break out now $5.90 secondary to the diagonal downtrend line and price presently cross at $5.90. volume should come in heavy on the break and hold of $5.92. amazing it works like that. through $5.90, $12 targets, on the fast side. days, weeks a couple of months. Look left. not to get ahead of us but what's the next level after 12? ty The .32% retracement. schrts.co/rFRSxvVf |
|
|
|
Post by peppy on Jan 31, 2023 10:58:48 GMT -5
Looks a lot like a cup-and-handle there on the monthly, target $6.10 ? Point of break out , point of cup break out now $5.90 secondary to the diagonal downtrend line and price presently cross at $5.90. volume should come in heavy on the break and hold of $5.92. amazing it works like that. through $5.90, $12 targets, on the fast side. days, weeks a couple of months. Look left. |
|
|
|
Post by peppy on Jan 31, 2023 10:50:33 GMT -5
Looking at the daily chart, it scares me to think that it looks like a potential head and shoulders. The upcoming Q4 conf call should negate that, but who knows. The monthly is not showing that and it looks constructive to me but I don't like the looks of the daily. There is nothing I will do about it besides maybe selling some very short covered calls with expiration before 3/24. What do you think Peppi? I think MNKD price movement is looking good. The month closes today. MNKD broke out from a two year flag last month at $4.40. Price then hit $5.46. MNKD share price then retraced and tested the point of break out, share price held at $4.54 on the test, and has continued up this month. MNKD share price attempting to break out as volume is high today. MNKD MONTHLY chart .... schrts.co/xtPStUaQThe daily, it looked like a tight bull flag... that is my take. weehaw, the plan is working. $COMPQ monthly, this isn't my first rodeo. Price can bounce up to test the 20 month at 13,000; 10,000 has held for 4 months. MNKD is going to $12. Regarding the $compq, I can be wrong. schrts.co/qAHPCYCmschrts.co/qAHPCYCm |
|
|
|
Post by peppy on Jan 31, 2023 9:36:36 GMT -5
MNKD has volume out of the gate.
At 5 mins of trade
127,219 shares.
$5.31+0.16 (+3.11%)
As of 09:35AM EST. Market open.
$5.47 is a new high... let's see.
At 20 mins of trade,
342,413 shares.
5.34+0.19 (+3.69%)
As of 09:51AM EST. Market open.
30 mins of trade,
382,281 shares.
5.29+0.14 (+2.72%)
MNKD volume at 1 hour of trade,
472,108 shares.
Avg. Volume 4,389,191
$5.32+0.17 (+3.30%)
As of 10:30AM EST. Market open.
|
|
|
|
Post by peppy on Jan 30, 2023 16:09:28 GMT -5
|
|
|
|
Post by peppy on Jan 30, 2023 14:16:38 GMT -5
At the end of the day , doctors are making money off these drugs. Isn’t in their best interest too at least screen visits or phone call ? At the end of the day physicians offices need to make money, pay staff. It takes office staff to write and send pre-authorization request. It seems more efficient for the office to prescribe what is covered by health insurance coverage. |
|
|
|
Post by peppy on Jan 30, 2023 14:14:01 GMT -5
@sayhey I was initially talking to prc who said we need a more persistent and better sales team. Doctors aren’t unlike anyone else. Who likes having door to door salespeople show up at their house all the time? Or telemarketers blowing up your phone? The only reason we tolerate them at all (the vast majority of the time, if not completely) is because of the quid pro quo food they bring. They take care of our office staff with goodies, I give you an ear for a few minutes. We’re too busy during the daytime to entertain company. I barely talk to my wife during the day. Why would I spend that time with a stranger? I agree the issue is with leadership. You also can’t legally say anything that’s not in the literature. You can point to individual studies, but again, this stuff takes a long time, which is why we’re handed printed materials. To keep things concise and highlight the key memorable points when the salespeople are gone. I have always thought the way to sell Afrezza is to show the physicians the continuous glucose monitors of people who use afrezza. That is not in the literature. When surfactant was trialed, the physicians could see the arterial blood gases. Amazing when a drug can save the medical community so much money, all of the sudden eyes can see. They could see the children weaning off the 02 and the ventilator rate and pressures being able to be reduced. Continuous glucose monitor, you can see afrezza 4 unit peak at 30 mins and baseline at 90 mins. Blood glucose can be controlled. |
|
|
|
Post by peppy on Jan 30, 2023 10:08:54 GMT -5
The other issue that people aren’t (fully) taking into account, ar least as it pertains to MNKDs failed efforts with Afrezza is the access to physicians to sell as well as a convincing argument to prescribe. A lot of reps are having trouble breaking through offices to get a face to face with a physician. A lot of offices have stopped seeing reps after COVID- for reasons I can’t imagine other than just wanting an excuse to say no. On top of that, and I should probably verify with my rep because I haven’t asked explicitly, but I don’t think they buy lunch for office staffs because that gets really expensive really quickly. My rep said he’ll get his foot in the door and talk to staff, they’ll be kind to him, act like they like the product, and then never prescribe it. Happens often with reps because people are either too “polite” or cowardly to be honest. I’ve lived in 2 densely populated areas now that have been key targets for MNKDs sales team. Both times, you can sense the discouragement and almost lack of confidence in the reps. By that, I mean you can see they get rejected so many times and have so much difficulty selling the product that it weighs on them. It’s like they expect things to go wrong… probably because everything does. Outside of sayhey, I don’t know of a single human being that can run into a brick wall countless times and get back up for more. It’s hard to find those types, and even if we had them, I don’t think they’d be anymore successful- the barriers aren’t at their level to overcome. It’s a really hard sell to walk into a doctors office with a novel product (and one that carries baggage from a botched Exubera) and change minds. It’s different because you inhale it. That was ultimately the angle the first rep I worked with used. It was almost embarrassing the data they bring with them from the stat study to show superiority with an n of 24 for study participants. Then, if they do get a few prescriptions written, prescribers will give up once they inevitably run into countless prior authorizations and appeals in an office already inundated by frivolous paperwork. No one wants the hassle. To be honest, there’s no way I’d think twice about prescribing Afrezza based on what the reps have said and shown to me. If I didn’t do all the research myself, I wouldnt believe in the product enough to waste my time. Food for thought. I’m on the fence regarding if I want MNKD to go it alone or have a sales team. It depends on how good the results are. Anyone and their grandmother could sell Viagra. Doesn’t take talent to sell something with exceptional data and coverage. It’s more just a matter of getting boots on the ground and bringing food. "Anyone and their grandmother could sell Viagra." "Doesn’t take talent to sell something with exceptional data and coverage." Really? You think it was the exceptional data and coverage that sold Viagra? |
|
|
|
Post by peppy on Jan 29, 2023 13:11:32 GMT -5
I thought we have been through this many times - here are a few examples per Jenny Ruhl... There is nothing relevant there. They all say the same thing, high levels cause nerve damage. What they don't say is over how long, how regularly, and how high. You need to quantify the impact and that means answering those questions. Abstract The sinoatrial node (SAN) is the normal pacemaker of the heart and SAN dysfunction (SND) is common, but until recently the pathophysiology was incompletely understood. It was usually attributed to idiopathic age-related fibrosis and cell atrophy or ischaemia. It is now evident that changes in the electrophysiology of the SAN, known as electrical remodelling, is an important process that has been demonstrated in SND associated with heart failure, ageing, diabetes, atrial fibrillation and endurance exercise. Furthermore, familial SND has been identified and mutations have been characterised in key pacemaker genes of the SAN. This review summarises the current evidence regarding SAN function and the pathophysiology of SND. Keywords Sinoatrial node, pacemaking, sinus node dysfunction, sinus node disease, sick sinus syndrome, membrane clock, calcium clock, biological pacemaker, tachy-brady, atrial fibrillation Aged, have you ever made it so far into the Kreb's cycle as to get to electron transfer? The burning of a glucose molecule in the presence of oxygen to make the 33 ATP, the ATP used for election transfer, fascinating. The heart the largest muscle with nervous system interaction. |
|
|
|
Post by peppy on Jan 29, 2023 4:51:49 GMT -5
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System - The New York Times (nytimes.com) In this article, the writer explains the problem for many people on Medicare. Abbvie’s Humira represents 1/3 of their revenue based on the drug being initially approved for RA. However, they would tweak the drug by various means, like getting it approved for another indication—like Crohn’s disease and getting a new patent, thus getting a patent extension. This new patent prevents another company from offering a cheaper version. When Medicare patients use insulin and they hear they can get a refill for the most expensive insulin product on the market (Afrezza ) and pay only $35.00, they forget there is an insurance company or company with a self-insured healthcare plan for their employees that will make up the difference in the $35.00 and the actual cost the drug company is selling their drug. In this article, they explain one case where the patient’s company was a self-insured healthcare plan. They would pay the difference in the co-pay or special cap-on-cost of the drug, like the $35.00 insulin situation. But in the case of this article, the patient was using Humira, and the company was paying the total price for Humira, which is about $70,000.00 per year. This employee wasn’t even making $70,000.00 a year. The company offered her a special deal that would save the company 10s of thousands of dollars by letting her still get her Humira drug, plus she would get a vacation deal at no cost. The company would fly her to the Bahamas, she would see a medical doctor there, and the doctor would write her a prescription for a cheaper version of Humira for a four-month supply. So, the employer fly’s her to the Bahamas three times a year and they are saving a bundle of money by doing this. United Therapeutics is the master of doing what Abbvie is doing. For United, it is their major drug-Tyvaso. Times are changing---the gouging of drug companies is going to change, or our nation will go broke. For Abbvie, the deal they cut to keep competitors from launching their cheaper drug ended last month. "the doctor would write her a prescription for a cheaper version of Humira for a four-month supply" What cheaper version than Humira? What was she prescribed in the Bahamas? HUM IRA (adalimumab) Injection, has a black box warning. www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf-----.-INDICA TIONS AND USAGE------ HUMIRA is a tumor necrosis factor (TN of: Rheumatoid Arthritis (RA) (1.1) F) blocker indicated for treatment . Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. Juvenile Idiopathic Arthritis(JIA) (1,2) . Reducing signs and symptoms of moderately to severely active polyarticular JIA in pediatiic patients 4 years of age and older. Psoriatic Arthritis (PsA) (1.3) . Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. Ankylosing Spondylitis (AS) (1.4) . Reducing signs and symptoms in adult patients with active AS. Crohn's Disease (CD) (1.5) . Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to inflixiinab. |
|
